In contrast, AML patients with CEBPA double mutations had lower expression of TNFAIP2 than wild type CEBPA (Supplementary Fig. S3g, P < 0.001) or with single CEBPA mutation (Supplementary Fig. S3g, P = 0.025). This evidence concerns the gene TNFAIP2 and acute myeloid leukemia.